These analyses were designed to clarify the differences in TM9SF1 expression in ARDS patients, to better probe the clinical relevance and possible functional role of TM9SF1 as a novel personalized biomarker for the early-stage prediction of ARDS severity and patient prognosis, and to construct predictive models capable of the early identification of patients with severe disease and gauging their prognosis. This evidence concerns the gene TM9SF1 and acute respiratory distress syndrome.